(often associated with ATHENA trial contexts in heart disease research) is an experimental in vivo CRISPR gene-editing therapy designed to provide a one-time treatment for cardiovascular disease risk factors. It specifically targets the ANGPTL3 gene in the liver to permanently lower high levels of triglycerides (TG) and "bad" LDL cholesterol. 💡 Key Trial Results (Phase 1)
ANGPTL3 is a protein that normally inhibits enzymes that clear lipids from the blood. By "turning off" this gene, the body can more effectively remove fats. ATHENA HEART 310
The therapy is being tested for those with severe hypertriglyceridemia (sHTG), mixed dyslipidemia, and familial hypercholesterolemia (HoFH/HeFH). 🚀 Future Outlook (often associated with ATHENA trial contexts in heart
The treatment has been generally well-tolerated, with minor side effects like back pain or nausea reported during infusion. 🧬 Mechanism and Targets By "turning off" this gene, the body can
Targeted protein levels decreased by an average of 73%.
Detailed clinical summaries and press releases are available directly from CRISPR Therapeutics and medical news sources like Drug Discovery News . If you'd like to dive deeper into the research:
Unlike daily pills or bi-monthly injections, CTX310 aims for a durable, permanent solution by editing DNA directly: